Last reviewed · How we verify
Prefilled Syringe delivery of Golimumab
Prefilled Syringe delivery of Golimumab is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved.
At a glance
| Generic name | Prefilled Syringe delivery of Golimumab |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prefilled Syringe delivery of Golimumab CI brief — competitive landscape report
- Prefilled Syringe delivery of Golimumab updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Prefilled Syringe delivery of Golimumab
What is Prefilled Syringe delivery of Golimumab?
Prefilled Syringe delivery of Golimumab is a Small molecule drug developed by Merck Sharp & Dohme LLC.
Who makes Prefilled Syringe delivery of Golimumab?
Prefilled Syringe delivery of Golimumab is developed and marketed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
What development phase is Prefilled Syringe delivery of Golimumab in?
Prefilled Syringe delivery of Golimumab is FDA-approved (marketed).